$ARVN
Arvinas Inc

2024 Q4 Form 10-Q Financial Statement

#000165575924000131 Filed on October 30, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $102.4M
YoY Change 195.95%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $75.80M
YoY Change 235.4%
% of Gross Profit
Research & Development $86.90M
YoY Change 1.16%
% of Gross Profit
Depreciation & Amortization $1.100M
YoY Change -8.33%
% of Gross Profit
Operating Expenses $162.7M
YoY Change 49.95%
Operating Profit -$60.30M
YoY Change -18.4%
Interest Expense $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net $11.70M
YoY Change 17.0%
Pretax Income -$48.60M
YoY Change -23.94%
Income Tax $600.0K
% Of Pretax Income
Net Earnings -$49.20M
YoY Change -23.13%
Net Earnings / Revenue -48.05%
Basic Earnings Per Share -$0.68
Diluted Earnings Per Share -$0.68
COMMON SHARES
Basic Shares Outstanding 68.71M shares 68.65M shares
Diluted Shares Outstanding 72.10M shares

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.122B
YoY Change 12.33%
Cash & Equivalents $85.20M
Short-Term Investments $1.036B
Other Short-Term Assets $13.10M
YoY Change -5.76%
Inventory
Prepaid Expenses
Receivables $7.300M
Other Receivables $7.500M
Total Short-Term Assets $1.150B
YoY Change 11.28%
LONG-TERM ASSETS
Property, Plant & Equipment $6.800M
YoY Change -46.46%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $9.800M
YoY Change 2.08%
Total Long-Term Assets $17.60M
YoY Change -30.43%
TOTAL ASSETS
Total Short-Term Assets $1.150B
Total Long-Term Assets $17.60M
Total Assets $1.167B
YoY Change 10.28%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $17.70M
YoY Change -48.4%
Accrued Expenses $800.0K
YoY Change -98.61%
Deferred Revenue $199.2M
YoY Change -11.15%
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $200.0K
YoY Change 0.0%
Total Short-Term Liabilities $275.9M
YoY Change -13.05%
LONG-TERM LIABILITIES
Long-Term Debt $600.0K
YoY Change -25.0%
Other Long-Term Liabilities $304.6M
YoY Change 7.63%
Total Long-Term Liabilities $600.0K
YoY Change -25.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $275.9M
Total Long-Term Liabilities $600.0K
Total Liabilities $581.1M
YoY Change -3.33%
SHAREHOLDERS EQUITY
Retained Earnings -$1.487B
YoY Change 26.2%
Common Stock $100.0K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $586.0M
YoY Change
Total Liabilities & Shareholders Equity $1.167B
YoY Change 10.28%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$49.20M
YoY Change -23.13%
Depreciation, Depletion And Amortization $1.100M
YoY Change -8.33%
Cash From Operating Activities -$128.0M
YoY Change 50.94%
INVESTING ACTIVITIES
Capital Expenditures $700.0K
YoY Change -36.36%
Acquisitions
YoY Change
Other Investing Activities $51.20M
YoY Change -27.99%
Cash From Investing Activities $50.50M
YoY Change -27.86%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.400M
YoY Change -93.67%
NET CHANGE
Cash From Operating Activities -128.0M
Cash From Investing Activities 50.50M
Cash From Financing Activities 2.400M
Net Change In Cash -75.10M
YoY Change -425.11%
FREE CASH FLOW
Cash From Operating Activities -$128.0M
Capital Expenditures $700.0K
Free Cash Flow -$128.7M
YoY Change 49.83%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Trading Symbol
TradingSymbol
ARVN
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
68713098 shares
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
7300000 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0 usd
CY2024Q3 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
7500000 usd
CY2023Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
7200000 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
13100000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6500000 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
1149500000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
1280200000 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6800000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11500000 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1000000.0 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2500000 usd
CY2024Q3 arvn Collaboration Contract Asset And Other Assets
CollaborationContractAssetAndOtherAssets
9800000 usd
CY2023Q4 arvn Collaboration Contract Asset And Other Assets
CollaborationContractAssetAndOtherAssets
10400000 usd
CY2024Q3 us-gaap Assets
Assets
1167100000 usd
CY2023Q4 us-gaap Assets
Assets
1304600000 usd
CY2024Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
75900000 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
92200000 usd
CY2024Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
199200000 usd
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
163000000.0 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.68
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.68
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
72100000 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
72100000 shares
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001655759
dei Entity Registrant Name
EntityRegistrantName
ARVINAS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-2566120
dei Entity Address Address Line2
EntityAddressAddressLine2
395 Winchester Ave
dei Entity Address City Or Town
EntityAddressCityOrTown
New Haven
dei Entity Address State Or Province
EntityAddressStateOrProvince
CT
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
06511
dei City Area Code
CityAreaCode
203
dei Local Phone Number
LocalPhoneNumber
535-1456
dei Security12b Title
Security12bTitle
Common stock, par value $0.001 per share
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-2500000 usd
us-gaap Net Income Loss
NetIncomeLoss
-153800000 usd
us-gaap Net Income Loss
NetIncomeLoss
-212500000 usd
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.14
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.14
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.97
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54100000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
71900000 shares
us-gaap Net Income Loss
NetIncomeLoss
-153800000 usd
dei Entity Address Address Line1
EntityAddressAddressLine1
5 Science Park
us-gaap Net Income Loss
NetIncomeLoss
-153800000 usd
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
10000000.0 usd
dei Entity File Number
EntityFileNumber
001-38672
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
85200000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
311700000 usd
CY2024Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
0 usd
CY2024Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
1036400000 usd
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
949300000 usd
CY2023Q3 us-gaap Revenues
Revenues
34600000 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
86900000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
85900000 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
75800000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
22600000 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
162700000 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
108500000 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-60300000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-73900000 usd
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2600000 usd
CY2024Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
14300000 usd
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
10000000.0 usd
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
11700000 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
10000000.0 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-63900000 usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
600000 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-100000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-49200000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-64000000.0 usd
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.18
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.18
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-49200000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-64000000.0 usd
CY2024Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
7900000 usd
CY2023Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
3000000.0 usd
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-41300000 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-61000000.0 usd
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53600000 shares
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.68
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.68
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.18
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.18
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.14
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.14
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.97
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.97
CY2024Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10400000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10400000 shares
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9100000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9100000 shares
CY2024Q3 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
5000000 usd
CY2023Q3 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
10000000 usd
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q3 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P3M
CY2024Q3 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2024Q3 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2024Q3 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2024Q3 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2024Q3 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
5500000 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
800000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1900000 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
275900000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
257100000 usd
CY2024Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
304500000 usd
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
386200000 usd
CY2024Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
600000 usd
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
800000 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
100000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
500000 usd
CY2024Q3 us-gaap Liabilities
Liabilities
581100000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
644600000 usd
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
68700000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
68700000 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
68000000.0 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
68000000.0 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
100000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
100000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1486500000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1332700000 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2068300000 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1995700000 usd
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
4100000 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3100000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
586000000.0 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
660000000.0 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1167100000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1304600000 usd
CY2024Q3 us-gaap Revenues
Revenues
102400000 usd
us-gaap Revenues
Revenues
204200000 usd
us-gaap Revenues
Revenues
121600000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
264900000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
284500000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
131300000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
73300000 usd
us-gaap Operating Expenses
OperatingExpenses
396200000 usd
us-gaap Operating Expenses
OperatingExpenses
357800000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-192000000.0 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-236200000 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2700000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1100000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
41900000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
26600000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
39200000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
25500000 usd
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-48600000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-152800000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-210700000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000000.0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-700000 usd
CY2024Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
0 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
0 usd
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.97
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54100000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
71900000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
53600000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53600000 shares
us-gaap Net Income Loss
NetIncomeLoss
-212500000 usd
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
7200000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-146600000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-202500000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
600200000 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
24700000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-49200000 usd
CY2024Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2400000 usd
CY2024Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
7900000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
586000000.0 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
463600000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
16700000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-64000000.0 usd
CY2023Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1900000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
1100000 usd
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
36000000.0 usd
CY2023Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
3000000.0 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
457200000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
660000000.0 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
64900000 usd
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
7700000 usd
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
7200000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
586000000.0 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
564900000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
54900000 usd
us-gaap Net Income Loss
NetIncomeLoss
-212500000 usd
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
3900000 usd
us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
1100000 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
36000000.0 usd
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
10000000.0 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
457200000 usd
us-gaap Net Income Loss
NetIncomeLoss
-153800000 usd
us-gaap Net Income Loss
NetIncomeLoss
-212500000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
3500000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
3600000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
17100000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
11600000 usd
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0 usd
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
-900000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1500000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1400000 usd
us-gaap Capitalized Contract Cost Amortization
CapitalizedContractCostAmortization
3600000 usd
us-gaap Capitalized Contract Cost Amortization
CapitalizedContractCostAmortization
2000000.0 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-2600000 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0 usd
us-gaap Share Based Compensation
ShareBasedCompensation
64900000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
54900000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
7300000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
14700000 usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
300000 usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-2200000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
6400000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-12300000 usd
us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
3000000.0 usd
us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
0 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-16300000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
16000000.0 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1600000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1500000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-45500000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-117700000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-175200000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-264700000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
600800000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
665700000 usd
arvn Proceeds From Maturities Of Marketable Securities
ProceedsFromMaturitiesOfMarketableSecurities
538000000.0 usd
arvn Proceeds From Maturities Of Marketable Securities
ProceedsFromMaturitiesOfMarketableSecurities
873400000 usd
arvn Proceeds From Sale Of Marketable Securities
ProceedsFromSaleOfMarketableSecurities
0 usd
arvn Proceeds From Sale Of Marketable Securities
ProceedsFromSaleOfMarketableSecurities
52300000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1500000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2800000 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
100000 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-64200000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
257200000 usd
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
300000 usd
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
0 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
37100000 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1100000 usd
arvn Proceeds From Exercise Of Stock Options And Issuance Of Employee Stock Shares
ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares
7700000 usd
arvn Proceeds From Exercise Of Stock Options And Issuance Of Employee Stock Shares
ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares
3900000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7400000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
39900000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-232000000.0 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
32400000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
317200000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
86800000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
85200000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
119200000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
1600000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
9100000 usd
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Company’s unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amount of assets, liabilities, revenue and expenses. These estimates include assumptions and judgments based on historical experience, current conditions, future expectations and other factors the Company considers reasonable. These estimates are reviewed on an ongoing basis and revised as necessary. Actual results could differ from these estimates.</span></div>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks and Uncertainties</span></div>The Company is subject to a number of risks similar to other biotechnology companies in a similar stage, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new technological innovations, and the need to successfully commercialize and gain market acceptance of the Company’s products and to protect its proprietary technology. If the Company does not successfully obtain regulatory approval of its product candidates, it will be unable to generate revenue from product sales or achieve profitability.
CY2024Q3 arvn Cash Cash Equivalents Restricted Cash And Marketable Securities
CashCashEquivalentsRestrictedCashAndMarketableSecurities
1100000000 usd
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
85200000 usd
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
113700000 usd
CY2024Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
0 usd
CY2023Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
5500000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
85200000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
119200000 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1000000.0 usd
arvn Accounts Receivable After Allowance For Credit Loss Current Additions
AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions
8700000 usd
arvn Accounts Receivable After Allowance For Credit Loss Current Additions
AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions
21700000 usd
arvn Accounts Receivable After Allowance For Credit Loss Current Payments Received
AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived
1400000 usd
arvn Accounts Receivable After Allowance For Credit Loss Current Payments Received
AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived
7000000.0 usd
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
7300000 usd
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
15700000 usd
CY2023Q4 arvn Accounts Payable Contract Balances Current
AccountsPayableContractBalancesCurrent
13100000 usd
CY2022Q4 arvn Accounts Payable Contract Balances Current
AccountsPayableContractBalancesCurrent
5000000.0 usd
arvn Accounts Payable Contract Balances Current Additions
AccountsPayableContractBalancesCurrentAdditions
43500000 usd
arvn Accounts Payable Contract Balances Current Additions
AccountsPayableContractBalancesCurrentAdditions
31000000.0 usd
arvn Accounts Payable Contract Balances Current Payments
AccountsPayableContractBalancesCurrentPayments
42300000 usd
arvn Accounts Payable Contract Balances Current Payments
AccountsPayableContractBalancesCurrentPayments
6700000 usd
CY2024Q3 arvn Accounts Payable Contract Balances Current
AccountsPayableContractBalancesCurrent
14300000 usd
CY2023Q3 arvn Accounts Payable Contract Balances Current
AccountsPayableContractBalancesCurrent
29300000 usd
CY2023Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
9400000 usd
CY2022Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
10700000 usd
arvn Contract With Customer Assets Increase Decrease For Additions To Collaboration Agreements
ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements
3000000.0 usd
arvn Contract With Customer Assets Increase Decrease For Additions To Collaboration Agreements
ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements
0 usd
arvn Capitalized Contract Cost Amortization During Period
CapitalizedContractCostAmortizationDuringPeriod
3600000 usd
arvn Capitalized Contract Cost Amortization During Period
CapitalizedContractCostAmortizationDuringPeriod
2000000.0 usd
CY2024Q3 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
8800000 usd
CY2023Q3 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
8700000 usd
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
549200000 usd
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
623700000 usd
arvn Contract With Customer Liability Increase Decrease For Additions To Collaboration Agreements
ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements
130000000.0 usd
arvn Contract With Customer Liability Increase Decrease For Additions To Collaboration Agreements
ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements
1500000 usd
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
82000000.0 usd
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
119100000 usd
arvn Contract With Customer Liability Revenue Recognized From New Collaboration
ContractWithCustomerLiabilityRevenueRecognizedFromNewCollaboration
93500000 usd
arvn Contract With Customer Liability Revenue Recognized From New Collaboration
ContractWithCustomerLiabilityRevenueRecognizedFromNewCollaboration
0 usd
CY2024Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
503700000 usd
CY2023Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
506100000 usd
CY2024Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
503700000 usd
CY2024Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
84100000 usd
CY2024Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
153400000 usd
CY2024Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
105000000.0 usd
CY2024Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
57600000 usd
CY2024Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
59800000 usd
CY2024Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
43800000 usd
CY2024Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
503700000 usd
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
31300000 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
32600000 usd
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
24500000 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
21100000 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6800000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11500000 usd
CY2024Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1100000 usd
CY2023Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1200000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
3500000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
3600000 usd
CY2021Q2 us-gaap Land Subject To Ground Leases
LandSubjectToGroundLeases
160000 sqft
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9M
CY2024Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
500000 usd
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
500000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
1500000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
1500000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
1600000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
1500000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
400000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
500000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
900000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
0 usd
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
900000 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
17700000 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
17800000 usd
CY2024Q3 arvn Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
29100000 usd
CY2023Q4 arvn Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
43100000 usd
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
19900000 usd
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
25700000 usd
CY2024Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
4100000 usd
CY2023Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
700000 usd
CY2024Q3 arvn Accrued General And Administrative And Commercial Current
AccruedGeneralAndAdministrativeAndCommercialCurrent
2700000 usd
CY2023Q4 arvn Accrued General And Administrative And Commercial Current
AccruedGeneralAndAdministrativeAndCommercialCurrent
2400000 usd
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2400000 usd
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2500000 usd
CY2024Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
75900000 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
92200000 usd
CY2024Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
200000 usd
CY2023Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
200000 usd
CY2024Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
600000 usd
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
800000 usd
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
0 usd
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
200000 usd
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
200000 usd
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
200000 usd
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
200000 usd
CY2024Q3 us-gaap Long Term Debt
LongTermDebt
800000 usd
CY2023Q3 us-gaap Interest Expense
InterestExpense
0 usd
us-gaap Interest Expense
InterestExpense
0 usd
us-gaap Interest Expense
InterestExpense
0 usd
CY2024Q3 us-gaap Interest Expense
InterestExpense
0 usd
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
24700000 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
16700000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
64900000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
54900000 usd
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
75100000 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y2M12D
arvn Share Based Compensation Arrangement By Share Based Payment Award Inducement Grants
ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants
255611 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
27.69
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
22.51
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
3600000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
900000 usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
600000 usd
CY2024Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.013
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2024Q3 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2024Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.013
CY2023Q3 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2023Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000000.0 usd
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.006
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-700000 usd
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.003
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.006
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.003
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-49200000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-64000000.0 usd
us-gaap Net Income Loss
NetIncomeLoss
-153800000 usd
us-gaap Net Income Loss
NetIncomeLoss
-212500000 usd
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
72100000 shares
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
72100000 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54100000 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54100000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
71900000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
71900000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
53600000 shares

Files In Submission

Name View Source Status
0001655759-24-000131-index-headers.html Edgar Link pending
0001655759-24-000131-index.html Edgar Link pending
0001655759-24-000131.txt Edgar Link pending
0001655759-24-000131-xbrl.zip Edgar Link pending
arvn-20240930.htm Edgar Link pending
arvn-20240930.xsd Edgar Link pending
arvn-20240930x10qex311.htm Edgar Link pending
arvn-20240930x10qex312.htm Edgar Link pending
arvn-20240930x10qex321.htm Edgar Link pending
arvn-20240930x10qex322.htm Edgar Link pending
exhibit101-terminationof.htm Edgar Link pending
exhibit101-terminationof001.jpg Edgar Link pending
exhibit101-terminationof002.jpg Edgar Link pending
exhibit101-terminationof003.jpg Edgar Link pending
exhibit101-terminationof004.jpg Edgar Link pending
exhibit101-terminationof005.jpg Edgar Link pending
exhibit101-terminationof006.jpg Edgar Link pending
exhibit101-terminationof007.jpg Edgar Link pending
exhibit101-terminationof008.jpg Edgar Link pending
exhibit101-terminationof009.jpg Edgar Link pending
exhibit101-terminationof010.jpg Edgar Link pending
exhibit101-terminationof011.jpg Edgar Link pending
exhibit101-terminationof012.jpg Edgar Link pending
exhibit101-terminationof013.jpg Edgar Link pending
exhibit101-terminationof014.jpg Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
arvn-20240930_def.xml Edgar Link unprocessable
arvn-20240930_lab.xml Edgar Link unprocessable
arvn-20240930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
arvn-20240930_htm.xml Edgar Link completed
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
arvn-20240930_cal.xml Edgar Link unprocessable